CD10和CD34在原发性肝癌中的表达及其意义

摘要/Abstract

摘要： 目的探讨CD10和CD34在原发性肝癌中的生物学作用,开展相关表达分析及临床意义探究。方法选取2021年3月至2024年3月于南京中医药大学附属无锡医院接受手术治疗的56例原发性肝癌患者,运用免疫组织化学Envision法,对术后癌组织样本中CD10 和CD34的蛋白表达情况进行检测。首先利用Spearman相关分析计算CD10与CD34之间的相关系数,以评估两者表达的相关性。其次,探讨CD10 和CD34表达水平与患者临床病理指标(包括年龄分布、性别差异、肿瘤分期情况)之间的潜在联系。进一步采用多种统计学方法深入评估CD10和CD34在原发性肝癌预后判断中的价值。通过绘制ROC曲线,量化分析两种标志物对患者生存状态的预测效能,明确其诊断准确性。利用Kaplan-Meier法构建生存曲线,系统计算患者生存率,并运用Log-rank检验,对比不同表达水平组间的生存差异。最后,借助Cox比例风险回归模型,整合CD10、CD34表达情况及其他临床变量,全面剖析各因素对患者预后的影响,筛选出具有独立预测价值的预后因素。结果免疫组化检测结果显示,56例原发性肝癌术后组织样本中,CD10阳性表达18例,阳性率达32.14%;CD34阳性表达28例,阳性率为50.00%。相关性分析表明,二者表达存在显著正相关关系(r=0.431,P=0.006),提示CD10 与CD34在肝癌组织中的表达变化具有协同特征。CD10 阳性表达率在不同性别间存在显著差异(χ²=4.038,P<0.05),提示CD10表达可能受性别因素影响。CD34的阳性表达与患者预后相关(χ²=6.402,P<0.05)。经分析,CD10的ROC曲线下面积(AUC)为 0.579(标准误0.095,95% CI:0.392~0.766),显示其对原发性肝癌的预测准确度欠佳;而 CD34的AUC达0.704(标准误0.085,95% CI:0.538~0.870),提示该指标具备较高的预测价值。Kaplan-Meier生存分析结果表明,CD10和CD34的表达均显著影响患者生存状况(P<0.05)。Cox回归模型分析显示,肿瘤大小、CD10及CD34表达均与肝癌预后显著相关(P<0.05),是影响患者预后的关键因素。结论 CD10和CD34在肝癌中均有较高阳性表达,且呈较高程度正相关;预后分析显示CD10和CD34的阳性表达能较好预判患者术后生存状态,对患者术后生存时间的影响有统计学意义。CD10和CD34可作为肝癌预后判断的指标。

关键词: 原发性肝癌, 肝细胞, CD10, CD34, 预后

Abstract: Objective To explore the biological roles of CD10 and CD34 in primary liver cancer (PLC), this study conducted analyses on their expressions and explored the clinical significance. Methods A total of 56 patients who underwent surgical resection for primary liver cancer at Wuxi Hospital Affiliated to Nanjing University of Traditional Chinese Medicine between March 2021 and March 2024 were enrolled. Immunohistochemistry Envision staining was used to detect CD10 and CD34 protein expression in post-operative cancer tissues. Spearman correlation analysis quantified the correlation coefficient between CD10 and CD34 expression to evaluate the correlation of them. Associations between marker levels and clinicopathological features (age, gender, tumor stage) were examined. Multiple statistical methods evaluated the prognostic value of CD10 and CD34 in PLC. Receiver operating characteristic (ROC) curves determined diagnostic accuracy. Kaplan-Meier survival curves and Log-rank tests compared survival outcomes across expression levels, and the Cox proportional hazards model identified independent prognostic factors by integrating marker expression with other clinical variables. Results Immunohistochemistry revealed CD10 positivity in 18 of 56 cases (32.14%) and CD34 positivity in 28 cases (50.00%). A significant positive correlation was observed between CD10 and CD34 expression (r=0.431, P=0.006), indicating coordinated regulation in liver cancer tissues. In PLC, CD10 expression differed significantly by gender (χ²=4.038, P<0.05), suggesting gender-dependent regulation. CD34 positivity correlated with patient prognosis (χ²=6.402, P<0.05). CD10 exhibited poor diagnostic accuracy, with an area under the ROC curve (AUC) of 0.579 (standard error 0.095, 95%CI: 0.392~0.766), whereas CD34 showed the higher predictive value (AUC=0.704, standard error 0.085, 95%CI: 0.538~0.870). Kaplan-Meier survival analysis showed that the expressions of CD10 and CD34 both had a significant impact on the survival status of patients.Cox regression analysis identified tumor size, CD10, and CD34 expression as key predictors of liver cancer prognosis (all P<0.05). Conclusion CD10 and CD34 have high positive expression in PLC and were positively correlated. CD10 and CD34 could predict the survival status and the survival time of patients after operation. Both CD10 and CD34 were prognostic indicators.

Key words: Primary liver cancer, CD10, CD34, Prognosis

郭飞宇, 李伟, 景发. CD10和CD34在原发性肝癌中的表达及其意义[J]. 肝脏, 2026, 31(6): 831-833.

Guo Feiyu, Li Wei, Jing Fa. Unveiling the expression profiles and functional significance of CD10 and CD34 in primary liver cancer[J]. Chinese Hepatolgy, 2026, 31(6): 831-833.

/ 推荐

参考文献

[1] Fu Y, Maccioni L, Wang X W, et al. Alcohol-associated liver cancer[J]. Hepatology, 2024,80(6): 1462-1479.
[2] Yang F, Hilakivi-Clarke L, Shaha A, et al. Metabolic reprogramming and its clinical implication for liver cancer[J]. Hepatology, 2023,78(5): 1602-1624.
[3] Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma[J]. Hepatology, 2023,77(5): 1773-1796.
[4] Cheng K, Cai N, Zhu J, et al. Tumor-associated macrophages in liver cancer: from mechanisms to therapy[J]. Cancer Commun (Lond), 2022,42(11): 1112-1140.
[5] Mackowiak B, Fu Y, Maccioni L, et al. Alcohol-associated liver disease[J]. J Clin Invest, 2024,134(3).
[6] 郭飞宇, 杨军, 熊书名, 等. 表皮生长因子受体和胸苷酸合成酶在原发性肝癌中的表达和意义[J]. 中华肝脏病杂志, 2018,26(9): 666-669.
[7] Wang S, Xiao Y, An X, et al. A comprehensive review of the literature on CD10: its function, clinical application, and prospects[J]. Front Pharmacol, 2024,15:1336310.
[8] Wang H Y, Louis H, Costello C L, et al. A CD10-negative adult B-lymphoblastic leukaemia with amplification of KMT2A without rearrangement: a case report and review of the English literature[J]. Br J Haematol, 2024,205(1): 364-367.
[9] Meng Y, Ye F, Nie P, et al. Immunosuppressive CD10(+)ALPL(+) neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells[J]. J Hepatol, 2023,79(6): 1435-1449.
[10] Sasaki Y, Murai S, Okamura R, et al. CD5-and CD10- positive MYC and BCL2 double-expressor diffuse large B-cell lymphoma with MYD88L265P mutation: a case report and literature review[J]. Rinsho Ketsueki, 2023,64(1): 42-48.
[11] Castillo D R, Park D, Jeon W J, et al. Unveiling the prognostic significance of BCL6+/CD10+ mantle cell lymphoma: meta-analysis of individual patients and systematic review[J]. Int J Mol Sci, 2023,24(12).
[12] Hino C, Pham B, Gray A L, et al. Clinicopathologic features and treatment of CD10-positive mantle cell lymphoma: a case report and review of literature[J]. Pathol Oncol Res, 2022,28:1610588.
[13] Carreras J, Hamoudi R, Nakamura N. Artificial intelligence and classification of mature lymphoid neoplasms[J]. Explor Target Antitumor Ther, 2024,5(2): 332-348.
[14] Qorbani A, Horvai A. Atypical spindle cell/pleomorphic lipomatous tumor[J]. Surg Pathol Clin, 2024,17(1): 97-104.
[15] Torlakovic E E, Calvo K R, George T, et al. Clinical applications of bone marrow CD34 immunohistochemistry (BM CD34 IHC) assay: international council for standardization in Hematology (ICSH) Guidelines[J]. Int J Lab Hematol, 2024.
[16] Stanek J. E-cadherin/CD34 double immunostaining in placental diagnosis[J]. Pol J Pathol, 2024,75(3): 171-181.
[17] Tariq A R, Lee M, Kim M. Endothelial progenitor cells: a brief update[J]. Int J Stem Cells, 2024,17(4): 374-380.
[18] Capelli D. FLT3-mutated leukemic stem cells: mechanisms of resistance and new therapeutic targets[J]. Cancers (Basel), 2024,16(10).
[19] Bigi F, Manzato E, Barbato S, et al. Impact of anti-CD38 monoclonal antibody therapy on CD34⁺ hematopoietic stem cell mobilization, collection, and engraftment in multiple myeloma patients-a systematic review[J]. Pharmaceuticals (Basel), 2024,17(7).
[20] Gama H, Albuquerque R, Campos W D, et al. CD34 immunostaining adds specificity to microvascular invasion analysis in hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2023,10:91-98.